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The SNAIL-related zinc-ﬁnger transcription factor,
SLUG (SNAI2), is critical for the normal development
of neural crest-derived cells and loss-of-function SLUG
mutations have been proven to contribute to piebaldism
and Waardenburg syndrome type 2 in a dose-dependent
fashion. While aberrant induction of SLUG has been
documented in cancer cells, relatively little is known about
the consequences of SLUG overexpression in malignancy.
To investigate the potential role of SLUG overexpression
in development and in cancer, we generated mice carrying
a tetracycline-repressible Slug transgene. These mice were
morphologically normal at birth, and developed mesench-
ymal tumours (leukaemia and sarcomas) in almost all
cases examined. Suppression of the Slug transgene did not
rescue the malignant phenotype. Furthermore, the BCR–
ABL oncogene, which induces Slug expression in leukae-
mic cells, did not induce leukaemia in Slug-deﬁcient mice,
implicating Slug in BCR–ABL leukaemogenesis in vivo.
Overall, the ﬁndings indicate that while Slug overexpres-
sion is not sufﬁcient to cause overt morphogenetic defects
in mice, they demonstrate a speciﬁc and critical role for
Slug in the pathogenesis of mesenchymal tumours.
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1. Introduction
Recent years have seen the identiﬁcation of numerous
genes that regulate embryonic development, and the
discovery that mutation of such genes is implicated in
genetic disorders in humans and mice, ranging from
birth defects to cancer. SLUG (SNAI2), a vertebrate-
speciﬁc Snail-related gene that was ﬁrst identiﬁed in the
neural crest and developing mesoderm in the chick
embryos (Nieto, 1994), is expressed by cells undergoing
epithelial-to-mesenchymal-transition (EMT) in the de-
veloping chick embryo, where it is critical in formation
of the primitive streak, endocardial cushions, deconden-
sing somites and in closure of the palate. It has
conserved and divergent roles in the chick and mouse
embryo (Sefton et al., 1998), with evidence that the
functional mouse homologue of cSlug is in fact Snail
(Nieto, 2002), which is essential for gastrulation, EMT
and cell survival in the mouse (Sefton et al., 1998;
Sanchez-Martin et al., 2004).
In contrast, Slug-deﬁcient mice are viable and have a
white forehead blaze, patchy depigmentation of the
ventral body, tail and feet and macrocytic anaemia and
infertility, inferring an essential role for Slug in
melanocytes, haematopoietic stem cells and germ
cells (Perez-Losada et al., 2002). Slug is expressed in
migratory but not premigratory neural crest cells (Jiang
et al., 1998), where it is necessary for melanoblast
migration and /or survival but not for neural
crest formation (Sanchez-Martin et al., 2002), as
well as being expressed in the craniofacial mesenchyme,
developing bone, endocardial cushions and cardiac
outﬂow tracts, and mesenchymal components of the
lungs, kidneys and gut (Oram et al., 2003).
The postnatal expression of SLUG (SNAI2) and the
effects of SLUG deletion are similar in mouse and
human (Cohen et al., 1998; Inukai et al., 1999; Perez-
Losada et al., 2002; Sanchez-Martin et al., 2002; Oram
et al., 2003). Heterozygous deletion of the SNAI2 gene
results in human piebaldism (Sanchez-Martin et al.,
2003), while a homozygous deletion has been detected in
two individuals with Waardenburg disease type 2
(Sanchez-Martin et al., 2002). In humans, SLUG maps
to chromosome 8q11.21, comprises three exons and
codes for a 268 aa (29 kDa) protein that contains ﬁve
zinc-ﬁnger domains (Cohen et al., 1998).
Slug contributes to the function of the stem cell factor
c-kit signalling pathway (Perez-Losada et al., 2002) and
mediates the radioresistance biological function of the
SCF/kit (Inoue et al., 2002; Perez-Losada et al., 2003).
SLUG expression is found in t(17;19) leukaemic cells
(Inukai et al., 1999) rhabdomyosarcoma cells expressing
the translocation PAX3-FKHR (Khan et al., 1999), and
in breast cancer, where it is strongly correlated with loss
of E-cadherin (Hajra et al., 2002). These previous
observations of aberrant SLUG expression in human
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cancer cells (Inukai et al., 1999; Khan et al., 1999; Hajra
et al., 2002) lead us to investigate the role of SLUG
overexpression in malignancy by generating and analys-
ing Slug-overexpressing mice. These mice did not exhibit
morphological defects at birth, but did develop me-
senchymal cancers similar to those associated with
SLUG expression in humans. The leukaemic phenotype
seen in Slug-overexpressing mice could not be rescued
by suppression of the Slug transgene. In contrast,
leukaemia did not occur in compound heterozygous
mice, expressing the BCR–ABL oncogene but deleted
for both alleles of Slug (Slug/, BCR–ABLþ ). Taken
together, these ﬁndings indicate that alteration of SLUG
expression plays a speciﬁc and critical role in the
pathogenesis of cancer in vivo, notably in BCR–ABL-
associated leukaemias.
Results
Derivation of CombitTA-Slug mice
In order to determine the effect of upregulation of
SLUG expression in malignancy, we generated trans-
genic mice using the Combi-tTA system, in which the
expression of Slug gene could be exogenously regulated.
This system, which has the transactivator and the tet-
operator minimal promoter driving the expression gene
unit on a single plasmid (Schultze et al., 1996), ensures
the integration of the transactivator and reporter gene
units in equal copy numbers in a direct cis-conﬁguration
at the same chromosomal locus and prevents genetic
segregation of the control elements during breeding.
Insertion of the mSlug gene under the control of the
tetO-minimal promoter yielded the plasmid CombitTA-
Slug (Figure 1a). This was analysed in a cell system,
using a murine haematopoietic precursor Ba/F3 cell line
(Palacios and Steinmetz, 1985). In the absence of
tetracycline, the tet-repressor protein (fused to the viral
VP16 transactivator domain) binds to an engineered tet-
operator minimal promoter and activates Slug tran-
scription (CombitTA-Slug). In the presence of the
tetracycline, binding is abolished and the promoter
silenced (Figure 1a). CombitTA-Slug expression was
determined in transfected Ba/F3 cells after culturing for
2 days in the presence or absence of tetracycline
(Figure 1b). CombitTA-Slug was detected in Ba/F3
cells without tetracycline, but not in cells cultured with
tetracycline (20 ng/ml). The physiological relevance of
the CombitTA-Slug suppression was conﬁrmed in vitro
by assaying survival of Ba/F3 cells expressing Combit-
TA-Slug 24 h after IL-3 withdrawal. The effects of Slug
expression on cell growth were evaluated by analysing
internucleosomal DNA cleavage, leading to the forma-
tion of DNA ladders in agarose gels, which is a hallmark
of apoptosis. Normally, Slug expression protects Ba/F3
cells from apoptosis following IL-3 withdrawal (Inukai
et al., 1999) and, as we demonstrated, the level of
CombitTA-Slug expression was sufﬁcient in Ba/F3 cells
to prevent cell death. A DNA cleavage ladder was
observed in the Ba/F3 cells transfected with the empty
plasmid undergoing apoptosis in response to IL-3
withdrawal, but not in Slug-expressing Ba/F3 cells.
The sensitivity to IL-3 removal was restored by the
addition of tetracycline (Figure 1c,d).
We generated two separate transgenic lines for
CombitTA-mSlug (58A, 58B) (Figure 2a). In both lines,
the CombitTA-Slug expression was detected in all
tissues analysed (Figure 2b). Intercrossing of Combit-
TA-Slug mice and Slug-deﬁcient mice rescued the null
phenotype (discernable as a characteristic anaemia and
depigmentation), conﬁrming the efﬁcacy of the Combi-
TA-Slug transgene in vivo. The CombitTA-Slug expres-
sion was the result of transactivation as the suppression
of expression to undetectable values was conﬁrmed
when mice were supplied with tetracycline in their
drinking water (4mg/ml for 4 weeks) (Figure 2c).
CombitTA-Slug mice show no morphological
abnormalities
Cohorts of Combi-tTA-Slug mice were generated to
analyse the effect of the Slug expression in vivo. A total
of 77 transgenic animals (48 mice corresponded to line
58A and 29 mice to line 58B) and 53 control animals
were used in this study. Both transgenic lines were
analysed in detail and similar phenotypic features were
seen in both lines. Combi-Slug mice were born alive
without overt morphological abnormalities, and were
fully fertile with no differences apparent in the progeny.
Autopsy of pups, including extensive histological
analysis, revealed no abnormality of the kidneys, skin,
brain or gastrointestinal tract of CombitTA-Slug mice,
indicating that this level of overexpression of Slug does
not perturb normal embryonic development. Appro-
ximately 20% of CombitTA-Slug mice died suddenly
between 6 and 8 months of age with cardiomegaly and
congestive heart failure on autopsy. Histological exam-
ination of CombitTA-Slug mice hearts showed no
evidence of cardiac hypertrophy or ﬁbrosis with similar
cardiac myocyte cross-sectional areas to wild-type
controls (Masson’s trichrome staining, data not shown).
Cancer development in CombitTA-Slug mice
We next analysed whether the remaining CombitTA-
Slug mice (62) develop cancer. All these CombitTA-Slug
mice became unwell from approximately 9 months of
age onwards (the age range for tumour development was
from 9 to 14 months), with clinical manifestations that
included decreased physical activity, tachypnea, pilo-
erection, shivering and sustained weight loss, prior to
killing. The cancers, which were all mesenchymal in
origin, were acute leukaemia in 90% of CombitTA-Slug
mice and soft-tissue sarcoma in the remaining 10%
(Figure 3a,b). No epithelial tumours were seen in any of
the CombitTA-Slug mice analysed, even though with
ubiquitous expression of CombitTA-Slug. Macroscopic
analysis of these animals showed splenomegaly
(Figure 3a) or sarcomas (Figure 3b). Detailed analysis
of the sarcoma tumour cells established the diagnosis as
angiosarcoma (three cases), liposarcoma (two cases),
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chondrosarcoma (one case), and ﬁbrosarcoma (one
case). We detected one type of sarcoma per animal
although three of them also develop an acute leukaemia.
Histological analysis revealed marked leukaemic
cell inﬁltration of haematopoietic and nonhaematopoie-
tic tissues. These leukaemic cells preferentially inﬁltrate
the kidney, lung, WAT, heart and liver (Figure 3c).
Peripheral blood mononuclear cells from leukaemic
mice were identiﬁed by ﬂow cytometry using
a combination of speciﬁc antibodies. These studies
deﬁned the acute leukaemias as acute B-cell lympho-
blastic leukaemia (60% of cases) or acute myeloid
leukaemia (40% of cases) (Figure 3d). The thymi were
normal.
To test the malignant potential of cells from the
CombitTA-Slug mice, 1 106 peripheral blood blast
cells from CombitTA-Slug leukaemias were injected
subcutaneously into 16 40-day old nude mice. All 16
mice developed progressive tumours within 4–7 weeks of
transplantation. The tumours in the nude mice were
histologically identical to the original leukaemias and
their clonal origin was conﬁrmed by CombitTA-Slug
PCR (data not shown). Overall, these data deﬁne that
the leukaemias generated in the CombitTA-Slug mice
were malignant mesenchymal cancers and indicate that
Slug does not require tumour formation before dis-
semination can takeplace.
Irreversibility of alterations induced by Slug
The above results support the hypothesis that Slug
expression facilitates cell migration (Sefton et al., 1998;
Perez-Losada et al., 2002). Therefore, abolition of Slug
overexpression might be expected to either halt or
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Figure 1 CombitTA-Slug: transgene construct, expression and effect of Slug on the survival of Ba/F3 cells deprived of growth factor.
(a) Schematic representation of the CombitTA-Slug vector used in this study. (b) Analysis of tetracycline-dependent Slug expression by
RT–PCR in Ba/F3 cells for Combi-Slug (tet, þ tet in the medium). The PCR products were transferred to a nylon membrane and
analysed by hybridization with a speciﬁc probe for Slug. Actin was used to check cDNA integrity and loading. (c) Survival of Ba/F3
cells expressing Slug in the absence of IL-3. Cells growing exponentially in IL-3 supplemented media were adjusted to 5 105 cells/ml
on day 0, and cultured after removal of IL-3. The cell number of viable cells is shown for BCR-ABLp190, Ba/F3 cells grown in the
presence of IL-3, Slug-transfected Ba/F3 cells grown in the absence of IL-3 and Ba/F3 cells transfected with the empty plasmid (Ba/F3-
CombitTA) grown in the absence of IL-3. BCR–ABL was used as a positive control of a gene that caused resistance to cell death. (d)
Cell death is accompanied by nucleosome laddering after IL-3 deprivation. Low molecular weight DNA was isolated 24 h after IL-3
deprivation from Ba/F3þBCR-ABLp190 (lane 1), Ba/F3 grown in the presence of IL-3 (lane 2), Ba/F3-Combi-Slug grown in the
absence of IL-3 and doxycycline (tet) (lane 3), Ba/F3-Combi-Slug grown in the absence of IL-3 and with doxycycline (þ tet) (lane 4),
Ba/F3-CombitTA grown in the absence of IL-3 and doxycycline (tet) (lane 5), and Ba/F3-CombitTA grown in the absence of IL-3
and with doxycycline (þ tet) (lane 6). The time of treatment with doxycycline was 48 h. DNA was end-labelled, resolved by
electrophoresis in a 2% agarose gel and visualised by autoradiography
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reduce the growth and/or spread of the Slug-expressing
cells. To assess this, 10 leukaemic CombitTA-Slug mice
were evaluated for disease progression by ﬂow cytome-
try prior to and following administration of tetracycline
(4 g/l in the drinking water for 2 weeks, a dose sufﬁcient
suppress exogenous Slug expression) (Figure 4a). None
of the CombitTA-Slug mice exhibited amelioration of
the leukaemic phenotype despite complete CombiTA-
Slug suppression: ﬂow cytometry analysis identiﬁed the
persistence of leukemic cells in the peripheral blood
(Figure 4b) with inﬁltration of nonhaematopoietic
tissues evident on histology (Figure 4b). Autopsy of
these animals identiﬁed cardiomegaly. Thus, these
results show that the alterations, induced by Slug,
become independent of Slug overexpression.
Suppression of Slug blocks in vivo leukaemia development
of BCR–ABLp190
A critical step in understanding how malignant trans-
formation is mediated by cancer-associated oncogenes
(such as BCR–ABL) is to identify target genes and
pathways, which allow cells to grow outside their
normal environment (Sanchez-Garcia, 1997). Although
we have shown that Slug is sufﬁcient to generate
leukaemias and sarcomas and that the growth of these
cells becomes independent of Slug expression, these
results do not imply the speciﬁc requirement for Slug in
the malignant transformation. In order to address this
question, we used BCR–ABL oncogenesis (Shtivelman
et al., 1985; Clark et al., 1987; Sanchez-Garcia and
Gru¨tz, 1995) as a model. BCR–ABL upregulates the
expression of Slug in Ba/F3 cells, in blast cells of BCR–
ABL transgenic mice (Figure 5a, b) and in blast cells
from patients with Ph1-positive human leukaemias,
while SLUG mRNA is absent from normal human
lymphocytes (Figure 5c, lane 1). SLUG expression was
identiﬁed in t(9; 22)-positive cell lines derived from
patients with CML and Ph1-positive-ALL (K562, Nalm-
1 and TOM-1), in cells from Ph1-positive patients, and in
other leukaemic cell lines lacking the t(9;22), including
the 697 early B-lineage, the U937 myeloid, and the ALL-
SIL and KOPTI-KI T-cell lines (Figure 5c). These and
previous observations (10, 14) indicate that the aberrant
expression of SLUG is a common ﬁnding in mesench-
ymal tumours.
To show whether Slug is essential for BCR–ABL
leukaemogenesis, we generated BCR–ABLp190 transgenic
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Figure 2 CombitTA-Slug mice: transgene expression. (a) Identiﬁcation of transgenic mice by Southern analysis of tail snip DNA after
EcoRI digestion. We used the cDNA for mouse Slug for detection of the transgene. (b) Expression of the transgene was demonstrated
by RT–PCR. Expression of Combi-Slug and endogenous Slug was analysed by RT–PCR in tissues derived of Combi-Slug and control
mice. The PCR products were transferred to a nylon membrane and analysed by hybridization with a speciﬁc probe. Actin was used to
check cDNA integrity and loading. (c) Analysis of tetracycline-dependent Slug expression by RT–PCR in the bone marrow of Slug /
 mice for CombitTA-Slug (tet, þ tet in the medium). Tetracycline was given at 4mg/ml for 4 weeks. When the Slug expression is
suppressed, the phenotypic characteristics of Slug-deﬁcient mice are evident again in 4 weeks
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mice (Perez-Caro et al, in preparation) and examined
the leukaemogenic capacity of the BCR–ABLp190
oncogene in the presence and in the absence of Slug.
Two founder lines were generated and backcrossed into
the C57BL6 background to establish co-isogenic trans-
genic mice. Histological and phenotypic examination of
23 BCR–ABLp190 transgenic mice between 7 and 9
months of age conﬁrmed the presence of blast cells in
Figure 3 Mesenchymal cancer in CombiTA-Slug mice. (a) Macroscopic aspect and Haematoxylin/eosin-stained sections of the spleen
of wild-type and CombiTA-Slug mice. The spleen from CombiTA-Slug mice shows the effacement of the normal spleen architecture.
(b) Histologic appearance of a solid tumor (angiosarcoma) developed in CombiTA-Slug mice after Haematoxylin-eosin-staining. (c)
Histologic appearance of tissues in CombitTA-Slug mice. Haematoxylin/eosin-stained sections of the kidney, WAT, heart and lung of
wild-type and CombiTA-Slug mice. Slug-expressing cells disobey the social order of organ boundaries and migrate as individual cells
giving metastasis to different regions. Metastases are indicated by arrowheads. (d) Phenotypic characteristics of leukaemias of
CombiTA-Slug mice. Cells from peripheral blood of CombiTA-Slug mice were analysed by ﬂow cytometry. Cells were identiﬁed with
combinations of speciﬁc antibodies. Cells (10 000) were collected for each sample and dead cells were excluded from analysis by
propidium iodide staining
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haematopoietic and nonhaematopoietic tissues
(Figure 6a). Murine blast cells co-expressed B-cell and
myeloid markers (Figure 6b). Thus, these BCR–ABLp190
transgenic mice develop a disease similar to the human
situation, where BCR–ABLp190 is associated with a
B-cell acute leukaemia co-expressing myeloid markers
(Tabernero et al., 2001). To study the biology of
BCR–ABLp190-B-ALL in the absence of Slug, we
generated 10 BCR–ABLp190 transgenic mice homozy-
gous for the targeted mutation of the Slug gene. No
blast cells were detected on periodic analysis of
peripheral blood samples from the BCR–AB-
Lp190 Slug/ mice taken between 6 and 9 months of
age. At 12 months of age, all 10 BCR–ABLp190 Slug/
mice were killed and no evidence of leukaemia was
found at autopsy in any of the mice (Figure 6). These
results show that Slug is an essential mediator of BCR–
ABLp190 leukaemogenesis.
Discussion
Slug is a member of the Snail family of zinc-ﬁnger
transcription factors that share an evolutionarily con-
served role in mesoderm formation in invertebrates and
vertebrates (Nieto, 1994, 2002; Sefton et al., 1998), In
human and mouse, much of the knowledge regarding
the function of SLUG has been derived from analysis of
Figure 4 Phenotypes in CombiTA-Slug mice after suppression of Slug expression by tetracycline treatment. (a) Analysis of
tetracycline-dependent Slug expression in peripheral blood of mice transgenic for CombiTA-Slug (tet, þ tet in water) by RT–PCR. b-
Actin was used to check cDNA integrity and loading. (b) Flow cytometry phenotypic characteristics of cells from peripheral blood and
Haematoxylin/eosin-stained sections of tissues in CombiTA-Slug mice after suppression of Slug expression by tetracycline treatment
(4 g/l) for 4 weeks
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Figure 5 Expression of SLUG in BCR–ABL-expressing cells. Expression of both human and mouse Slug was analysed by RT-PCR.
The PCR products were transferred to a nylon membrane and analysed by hybridization with a speciﬁc probe. Actin or ABL was used
to check cDNA integrity and loading. (a) Analysis of Slug expression in the BCR–ABL-expressing Ba/F3 cells Ba/F3þ p190 (lane 1),
and Ba/F3þ p210 (unpublished mice) (lane 2) and in Ba/F3 cells (lane 3). (b) Expression of SLUG in the peripheral blood of BCR–
ABLp190 (human oncogene associated to B-cell ALL in humans) and BCR–ABLp210 (human oncogene associated to CML in humans)
transgenic mice. Peripheral blood of control mice (lane 1), BCR–ABLp190 (lanes 2–4) and BCR–ABLp210 (lanes 5–6) transgenic mice. (c)
SLUG is present in human leukaemic cell lines and in patient samples with t(9;22). Control human peripheral blood (lane 1), U937
myeloid leukaemic cell line (lane 2), ALL-SIL (lane 3) and KOPTI-KI (lane 4) T-cell leukaemic cells, the 697 pre-B leukaemic cell line
(lane 5), peripheral blood from patient samples with t(9; 22) (lanes 6–8, where patients #1 and #3 had a Ph-B-ALL, and patient #2 a
myeloid blast crisis), and K562 (lane 9), TOM-1 (lane 10), and Nalm-1 (lane 11) t(9; 22)-positive human leukaemic cell lines
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loss-of-function mutations (Jiang et al., 1998; Perez-
Losada et al., 2002; Sanchez-Martin et al., 2002, 2003),
which have demonstrated that SLUG is critical for
development of neural crest-derived cell lineages and
from insights into the interaction of SLUG with speciﬁc
oncogenes in human cancer, notably BCR–ABL (Inukai
et al., 1999; Khan et al., 1999, and this manuscript).
However, little is known as to how overexpression of
SLUGmight contribute to malignancy. We have utilized
the single-plasmid system containing the regulating and
expression elements of the original binary tetracycline
system to allow high induction and tight control of gene
expression by tetracycline in mice (Schultze et al., 1996)
to try to understand the relevance of SLUG to human
cancer development (Inukai et al., 1999; Khan et al.,
1999, this manuscript). In the mouse Slug is not
implicated in EMT (Sefton et al., 1998; Nieto, 2002),
while the Snail gene has been shown to trigger EMT, an
important pathway to acquisition of the invasive
phenotype in epithelial solid tumours (Cano et al.,
2000; Batlle et al., 2000). Our data support this
observation, with neither epithelial alterations nor
carcinomas in any of the CombitTA-Slug mice analysed.
However, these results cannot exclude a role for Slug in
carcinoma development in a context where murine
epithelial cells show or accumulate previous tumour
alterations.
The analysis of the Slug-expressing mice, with
reference to known human phenotypes, identiﬁed that
these mice develop mesenchymal cancers, mainly leu-
kaemias. A signiﬁcant percentage of mice develop
cardiomyopathy, but the temporal relation to the cancer
Figure 6 Requirement for Slug in tumorigenicity of BCR–ABL-expressing mice. (a) Histologic appearance of blood smears (Giemsa
staining) and tissues (Haematoxylin/eosin stained sections) and (b) Flow cytometry analysis of bone marrow (bm) and peripheral blood
(pb) cells with combinations of speciﬁc antibodies. Mice of the indicated genotypes were crossed and their offspring genotyped. Note
that BCRABLp190 mice developed a B-ALL characterized by the presence of blast cells co-expressing Mac-1 and B220. This
leukaemia is characterized by inﬁltration of spleen, liver and lung and the presence of lymphoblasts in blood smears. However, BCR–
ABLp190 mice do not show leukaemia into Slug / background
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favours the cardiomyopathy in the CombiTA–Slug mice
being a manifestation of the incipient leukaemia rather
than being a primary cardiomyopathy. In fact, endo-
genous Slug expression has not been identiﬁed in the
ventricles either on embryonic wholemount LacZ
staining (Sefton et al., 1998), immunohistochemistry
(Oram et al., 2003) or by analysis of tissue extracts (this
paper).
In the haematopoietic system, uncommitted progeni-
tor cells differentiate to mature cells, at which time the
expression of Slug is downregulated (Becker and Clarke,
2002; Inoue et al., 2002). When these normal uncom-
mitted progenitor cells migrate, it is believed that Slug
activation promotes their survival, permitting them to
carry out their function or, in the absence of appropriate
external stimuli, to undergo apoptosis (Metcalf, 1998).
Thus, the mesenchymal cancers observed in the Com-
bitTA-Slug mice represent an in vivo demonstration of
the idea that transformation depends upon genetic
changes that allow undifferentiated cells to grow outside
their normal environment (Figure 3). Thus, these results
provide evidence that Slug expression facilitates cell
migration (Perez-Losada et al., 2002). However, the
survival conferred by Slug, while reversible in vitro
(Figure 1), can escape such control in vivo. The
implications of these results in human stem cell-based
therapies should be considered.
Our ﬁndings further deﬁne the biological function
of Slug in cellular transformation by BCR–ABL
and conﬁrm that the BCR–ABL oncogene induces
SLUG expression. SLUG expression is being increas-
ingly recognized as an alteration in mesenchymal
tumours (both leukaemias and sarcomas) (Inukai
et al., 1999; Khan et al., 1999, and this paper),
suggesting that SLUG may be a critical factor in
tumour invasion not only of BCR–ABL-positive
leukaemias but also potentially in other mesenchymal
cancers. To show whether SLUG is required for
BCR–ABL leukaemogenesis, we demonstrate that the
leukaemogenic capacity of BCR–ABLp190 oncogene is
dependent on the presence of Slug, indicating that
Slug has a fundamental role in the biology of BCR–ABL
cancer cells. These results are consistent with a model in
which tumour cells harbouring the BCR–ABL
fusion protein constitutively express Slug, promoting
both aberrant survival of the tumour cell and migration
of the defective target cells into different environments
(Figure 7). The ﬁnding that SLUG is commonly
activated in mesenchymal tumour cells indicates
that it may have a broader role in cancer biology
than that speciﬁcally associated with BCR–ABL
transformation. SLUG expression might therefore
deﬁne a common pathway of cell invasion for
other leukaemias and sarcomas. In conclusion, in the
present work we have presented evidence that suggests
that Slug might represent a potentially important
mechanism of tumour invasion for mesenchymal tu-
mours. As such, SLUG can be considered as both a
marker of malignancy and an attractive target for
therapeutic modulation of invasiveness in the treatment
of human cancer.
Materials and methods
Generation of transgenic mice
The cDNA for mouse Slug was cloned into the Combi-tTA
vector (16). Linear DNA fragments for microinjection were
obtained by NotI digestion and injected into CBAC57BL/6J
fertilized eggs. We identiﬁed transgenic mice by Southern
analysis of tail snip DNA after EcoRI digestion as described
(Garcia-Hernandez et al., 1997). We used the cDNA for mouse
Slug for detection of the transgene. Founder mice were crossed
to the C57BL6 mice for ﬁve generations to establish co-
isogenic transgenic mice. Similar phenotypic features were seen
in all assays for both of the CombitTA-Slug transgenic lines
generated.
Mice heterozygous and homozygotes for the SlughD1
mutation generated by removing the genomic sequences of
the entire Slugh protein-coding region (SlughD1 mutant mice)
have been previously described (Jiang et al., 1998). Hetero-
zygous Slug þ / mice were bred to CombitTA-Slug
and BCR–ABLp190 transgenic mice to generate compound
heterozygotes. F1 animals were crossed to obtain null
Slug / mice heterozygous for CombitTA-Slug and BCR–
ABLp190 transgenic mice.
Histological analysis
Mice included in this study were subjected to standard
necropsy. All major organs were closely examined under the
dissecting microscope, and samples of each organ were
processed into parafﬁn, sectioned and examined histologically.
All tissue samples were taken from homogenous and viable
portions of the resected sample by the pathologist and ﬁxed
within 2–5min of excision. Haematoxylin- and eosin-stained
sections of each tissue were reviewed by a single pathologist
(TF). For comparative studies, age-matched mice were used
(wild-type or Combi-Slug mice in the continous presence of
tetracycline).
Cell culture
Cell lines used include Ba/F3 (Palacios and Steimetz,
1998) and Ba/F3 cells expressing the human proteins
BCR–ABLp190 (Ba/F3þ p190) and BCR–ABLp210 (Ba/
F3þ p210) (Sanchez-Garcia and Gru¨tz, 1995). Cells were
maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
supplemented with 10% fetal calf serum (FCS). When
required, 10% WEHI-3B-conditioned medium was added as
a source of IL-3.
Cell transfection and cell survival assay
Ba/F3 cells were transfected by electroporation (960mF, 220V)
with 20 mg of either CombitTA-Slug or empty vector
(CombitTA). The neomycin-resistant pool of cells (Ba/
F3þCombitTA-Slug) was analysed by RT–PCR for Combit-
TA-Slug expression in the presence and in the absence of
tetracycline (20 ng/ml). These cells were resistant to IL-3
withdrawal during growth in the absence of tetracycline. Cells
were screened for resistance to IL-3 withdrawal and cell
viability was determined by trypan blue exclusion.
Low molecular weight DNA analysis
Low molecular weight DNA was isolated as follows. Cells
were collected into 1.5ml of culture medium and microcen-
trifuged for 1min at 1500 r.p.m. (400 g), and the pellet was
suspended in 300 ml of proteinase K buffer. After overnight
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incubation at 551C, DNA was ethanol-precipitated, suspended
in 200ml of TE buffer containing 50 mg/ml of RNase A, and
incubated at 371C for 2 h. DNA was extracted with phenol and
chloroform and precipitated with ethanol. Aliquots of DNA
(2 mg) were end-labelled with a32-dCTP and electrophoresed
on 2% agarose gels. After electrophoresis, the gel was blotted
onto Hybond-N (Amersham) and autoradiographied for 2 h at
701C.
Reverse transcription-PCR (RT–PCR)
To analyse expression of CombitTA-Slug and endogenous
Slug in mouse cell lines and mice, RT was performed according
to the manufacturer’s protocol in a 20-ml reaction containing
50 ng of random hexamers, 3 mg of total RNA, and 200U of
Superscript II RNase H reverse transcriptase (GIBCO/BRL).
The sequences of the speciﬁc primers were as follows: Combi-
polyA-B1: 50-TTGAGTGCATTCTAGTTGTG-30; mSlugF:
50-GTTTCAGTGCAATTTATGCAA-30; mSlugB: 50-TTAT
ACATACTATTTGGTTG-30. Ampliﬁcation of b-actin RNA
served as a control to assess the quality of each RNA sample.
The PCR conditions used to amplify CombitTA-Slug and
endogenous Slug were as follows: 30 cycles at 941C for 1min
561C for 1min, and 721C for 2min. The PCR products were
conﬁrmed by hybridization with speciﬁc internal probes. To
analyse expression of SLUG in human cell lines and in
peripheral blood samples of Ph1-positive patients, the thermo-
cycling parameters for the PCR reactions and the sequences of
the speciﬁc primers were as follows: SLUG, 30 cycles at 941C
for 1min, 561C for 1min and 721C for 2min, sense primer
5’-GCCTCCAAAAAGCCAAACTA-30 and antisense primer
5’-CACAGTGATGGGGCTGTATG-30; c-ABL, 30 cycles at
941C for 1min, 561C for 1min, and 721C for 2min, sense
primer 5’-GTATCATCTGACTTTGAGCC-30 and antisense
primer 5’-GTACCAGGAGTGTTTCTCCA-30. Ampliﬁcation
of c-ABL mRNA served as a control to assess the quality of
each RNA sample.
Phenotype analysis
The following anti-mouse monoclonal antibodies from
Pharmingen were used for cytometry staining: CD45R/B220,
IgM, Mac1, Gr-1. Single-cell suspensions from the different
tissue samples obtained by routine techniques were incubated
with puriﬁed anti-mouse CD32/CD16 (Pharmingen) to block
binding via Fc receptors and with an appropriate dilution of
the different antibodies at room temperature or 41C, respec-
tively. The samples were washed twice with PBS and
resuspended in PBS. Dead cells in samples were excluded by
propidium iodide staining. The samples and the data were
analysed in a FACScan using CellQuest software (Becton
Dickinson).
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Figure 7 Model of the role of Slug in cancer development. (a) In the haematopoietic system, normal uncommitted progenitor cells
differentiate to mature cells. During this transition, the expression of Slug is downregulated (Becker and Clarke, 2002; Inoue et al.,
2002). These normal uncommitted progenitor cells are responsive to environmental cues, which regulate the number of mature cells
produced and limit the self-renewal of immature cells. When in physiological situations, these normal uncommitted progenitor cells
migrate, Slug would promote survival to allow them to carry out their function. If this is not achieved in a speciﬁc period of time, they
would undergo apoptosis as they have been deprived of required external signals. (b) In cancer development, the differentiation
capacity of the target cell is blocked, but inhibition of differentiation is not sufﬁcient for transformation because survival and
proliferation of target cells would be restricted to a particular microenvironment. Thus, other genetic changes that allow cells to grow
outside their normal environment in addition to mutations that block differentiation must exist. Fusion oncogenes created as a result
of chromosomal abnormalities associated with mesenchymal tumours (both leukaemias and solid tumours) block differentiation and
have the capacity to activate target genes such as Slug, which promotes survival (with independence of the required external signals)
and migration of the defective target cells into different environments
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Tumorigenicity assay
To test the tumorigenicity of the various cancers, 4- to 6-week-
old athymic (nude) male mice were injected subcutaneously on
both ﬂanks with 106 cells resuspended in 200 ml of phosphate-
buffered saline (PBS). The animals were examined for tumour
formation for up to 3 weeks.
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